0000000001220040

AUTHOR

Xuyang Lu

showing 1 related works from this author

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanc…

2015

Abstract Background: Taselisib (GDC-0032) is a next-generation PI3K inhibitor with increased anti-tumor activity against PIK3CA mutant (MT) cancers. Taselisib is an orally bioavailable, potent, and selective inhibitor of Class I PI3K alpha, delta, and gamma isoforms, with 30-fold less inhibition of the PI3K beta isoform relative to the PI3K alpha isoform. Preclinical data show that taselisib has enhanced activity against PI3K alpha isoform (PIK3CA) MT breast cancer cell lines and enhanced antitumor activity when combined with letrozole. Clinical data with single-agent taselisib also showed increased tumor shrinkage in patients with PIK3CA MT breast cancer as compared to patients with PIK3CA…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryLetrozoleCancermedicine.diseaseDysgeusiaRegimenBreast cancerOncologyTolerabilityInternal medicinePharmacodynamicsmedicinemedicine.symptomAdverse effectbusinessmedicine.drugCancer Research
researchProduct